Axovant Sciences given sell rating at Chardan Capital
NEW YORK: Axovant Sciences (NASDAQ:AXON)‘s stock had its “sell” rating reiterated by stock analysts at…
FEATURED
New drug hope for ‘childhood Alzheimer’s’ after global trials
Charity now set to build new pods for homeless people
Lilly’s Alzheimer’s super drug to be approved ‘any day’
Pensioner with ‘severe dementia’ living in care home is prosecuted
Inquest begins after man took wife’s end-of-life medication
Surveys show public support on euthanasia for mentally ill
INNOVATION
